Experimental CAR-T therapy aims to clear the way for kidney transplants in hard-to-match patients
NCT ID NCT07350837
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a single dose of AZD0120, a CAR-T cell therapy that targets two immune proteins (CD19 and BCMA), in 12 highly sensitized adults with end-stage kidney disease awaiting a transplant. The goal is to safely reduce the antibodies that make finding a compatible donor difficult. The study will monitor side effects and measure how well the therapy lowers these antibodies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD0120 (also called GC012F), a CAR-T cell therapy targeting CD19 and BCMA
What this could lead to
If successful, this could help highly sensitized patients receive a kidney transplant by reducing harmful antibodies that currently make transplantation risky or impossible.
What could go wrong
This is a very early, small trial (12 people) focused on safety. The therapy may not effectively lower antibodies, and there are risks of serious side effects like cytokine release syndrome or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital, Tongji Medical Collage of Huazhong University of Science & Technology
RECRUITINGWuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••